Literature DB >> 6305186

Treatment of varicella-zoster meningoencephalitis with acyclovir--demonstration of virus in cerebrospinal fluid by electron microscopy.

R W Steele, R E Keeney, R W Bradsher, E B Moses, B L Soloff.   

Abstract

Disseminated varicella-zoster (V-Z) infection developed in three immunocompromised patients, with direct invasion of the central nervous system by virus. For two of these patients, diagnosis was confirmed by electron microscopic examination of cerebrospinal fluid (CSF) and detection of viral particles. Extensive immunologic evaluation demonstrated impairment of cellular immune function. All were treated with acyclovir at a dose of 1,500 mg/m2/day for 5-7 days. Peak and trough plasma levels of this antiviral agent were monitored during the course of therapy and were shown to be well above V-Z virustatic levels. Clinical response was noted by the third day of therapy. Vesicles and CSF were culture negative at termination of treatment. Administration of this high dose of acyclovir was not associated with hematologic, immunologic, hepatic, renal, or gastrointestinal toxicity as judged by frequent laboratory and clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305186     DOI: 10.1093/ajcp/80.1.57

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Effectiveness of intravenous acyclovir in immunocompetent patient with herpes zoster encephalitis.

Authors:  M K Whyte; P W Ind
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

Review 2.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

3.  Subcortical type cognitive impairment in herpes zoster encephalitis.

Authors:  L Hokkanen; J Launes; E Poutiainen; L Valanne; O Salonen; J Sirén; M Iivanainen
Journal:  J Neurol       Date:  1997-04       Impact factor: 6.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.